☆ 4.5 Article

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

JOURNAL OF HEADACHE AND PAIN (2021)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

Bianca Raffaelli et al.

Summary: The cessation of CGRP(-receptor) antibodies migraine prophylaxis led to a significant increase in migraine frequency and acute medication intake over time. However, by weeks 13-16, the monthly migraine days were not significantly different from baseline values.

CEPHALALGIA (2022)

Add to Collection

Article Clinical Neurology

Erenumab Discontinuation After 12-Month Treatment A Multicentric, Observational Real-Life Study

Francesca Schiano di Cola et al.

Summary: After discontinuation of erenumab treatment, there was a rapid worsening of migraine symptoms, despite clinical improvement observed during retreatment. It may be necessary to reconsider the timing of treatment discontinuation due to the high frequency and degree of worsening seen during discontinuation.

NEUROLOGY-CLINICAL PRACTICE (2021)

Add to Collection

Article Clinical Neurology

Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial

Messoud Ashina et al.

Summary: This study found that treatment with erenumab led to a reduction in migraine frequency, improvement in health-related quality of life, and these effects were maintained for at least 5 years. No new safety signals were observed during the 5 years of exposure.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

Eleonora De Matteis et al.

Summary: The study evaluated early outcomes of erenumab discontinuation in migraine patients who had a continuous positive response. Results showed that most patients experienced worsening symptoms in the first 4 weeks after treatment cessation, although still lower than baseline. More than half of the patients had an early disease worsening, while others maintained their responder status after treatment completion. Further studies are needed to identify predictors of prolonged response to erenumab and determine the optimal treatment duration based on patients' characteristics.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Anesthesiology

Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache

Zhaohua Guo et al.

Summary: Studies suggest that blocking both CGRP and PACAP signaling pathways in TG neurons may be more effective in treating chronic migraine and posttraumatic headache than targeting individual pathways.

PAIN (2021)

Add to Collection

Review Medicine, Research & Experimental

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials

Dulanji K. Kuruppu et al.

Summary: Galcanezumab demonstrates early onset of action, maintenance of effect, and gradual reduction of effect upon treatment cessation in both patients with episodic and chronic migraine.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Clinical Neurology

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study

Andreas R. Gantenbein et al.

Summary: The study analyzed the effects of discontinuation of anti-calcitonin gene-related peptide antibodies treatment on migraine patients after 12 months of treatment, finding that migraine frequency increased in most patients after treatment interruption, necessitating re-prophylaxis. Therefore, limiting treatment to benefiting patients and periodically confirming the need for prophylaxis is recommended.

CEPHALALGIA (2021)

Add to Collection

Review Neurosciences

Pathophysiological Bases of Comorbidity in Migraine

Claudia Altamura et al.

Summary: Despite being commonly accepted as a disorder of the nervous system with a genetic basis, migraine is comorbid with various medical conditions including neurological, psychiatric, cardio- and cerebrovascular, gastrointestinal, metaboloendocrine, and immunological conditions. The bidirectional comorbidity between migraine and these diseases involves complex mechanisms that may induce and promote abnormal excitability in the brain, inflammatory responses, and energy imbalances, resulting in the activation of defense systems. Treatment of migraine should involve a multidisciplinary approach to identify and address possible risk and comorbidity factors.

FRONTIERS IN HUMAN NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study

Jiu-Haw Yin et al.

Summary: Patients with migraine, especially those with aura, tend to have unhealthy lifestyle factors and a higher prevalence of comorbid medical, psychiatric, and pain-related conditions compared to controls. Female gender, chronic migraine, and migraine with aura were associated with a greater number of significant comorbidities. Understanding the relationship between migraine and comorbid diseases is important for improving medical care and quality of life.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri et al.

Summary: In real-life settings, galcanezumab showed significant effectiveness in preventing HFEM and CM by reducing the number of migraine days and headache intensity, with good safety and tolerability. Patients who responded well to galcanezumab tended to have normal weight and a history of fewer failed preventive treatments.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Review Medicine, General & Internal

Migraine: epidemiology and systems of care

Messoud Ashina et al.

Summary: Migraine is a global neurovascular disorder that has negative impacts on patients, families, and society. Integrated and coordinated care systems can help reduce this burden. Low and middle-income countries face challenges in migraine care due to inadequate public health education and access to medication.

LANCET (2021)

Add to Collection

Article Clinical Neurology

Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti et al.

Summary: In a real-world setting, erenumab showed long-term effectiveness, safety, and tolerability in patients with high-frequency episodic migraine or chronic migraine with multiple prior preventive treatment failures. Positive predictors of responsiveness included allodynia in high-frequency episodic migraine, male sex, and baseline migraine frequency in chronic migraine, while negative predictors included psychiatric comorbidities and prior treatment failures in chronic migraine patients.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency

Ryotaro Ishii et al.

Summary: The study findings suggest that using a 15 headache day/month threshold to distinguish episodic and chronic migraine does not fully capture the burden of illness or reflect the treatment needs of patients, which has important implications for future refinements in migraine classification.

HEADACHE (2021)

Add to Collection

Review Clinical Neurology

Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review

Carrie R. Houts et al.

HEADACHE (2020)

Add to Collection

Article Clinical Neurology

A prospective real-world analysis of erenumab in refractory chronic migraine

Giorgio Lambru et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

Giuseppe Tringali et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

Central effects of erenumab in migraine patients An event-related functional imaging study

Christian Ziegeler et al.

NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

William Kielbasa et al.

CEPHALALGIA (2019)

Add to Collection

Article Clinical Neurology

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Stephen D. Silberstein et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

Bianca Raffaelli et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Article Medicine, General & Internal

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial

David W. Dodick et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Review Clinical Neurology

CGRP as the target of new migraine therapies - successful translation from bench to clinic

Lars Edvinsson et al.

NATURE REVIEWS NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial

Virginia L. Stauffer et al.

JAMA NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study

Holland C. Detke et al.

NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart Tepper et al.

LANCET NEUROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Fremanezumab for the Preventive Treatment of Chronic Migraine

Stephen D. Silberstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Pharmacology & Pharmacy

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

David Monteith et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.